David Gilligan
Research Subjects
David Gilligan has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
A. Brewster
Velindre Cancer Centre, Cardiff/GB
1 shared publicationAdam Peryt
Department of Thoracic Surgery Papworth Hospital NHS Foundation Trust Cambridge UK
1 shared publication- Alastair Greystoke
Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom
1 shared publication - Alexander Martin
Institute of Diagnostic and Interventional Radiology, University Hospital Zürich, 8091 Zürich, Switzerland
1 shared publication - Anil Rajendra
Grandview Medical Center , Arrythmia institute, Birmingham, AL
1 shared publication - Anna-Maria Shiarli
Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
1 shared publication
Latest Publications
- 1 June 2021
- Published by Elsevier in Lung Cancer
- Vol. 156, S57
MInimising radical RAdiotherapy Commencement time for Lung cancer to improve clinical outcomEs (MIRACLE)
- 1 June 2021
- Published by Elsevier in Lung Cancer
- Vol. 156, S57
MInimising radical RAdiotherapy Commencement time for Lung cancer to improve clinical outcomEs (MIRACLE)
- Top Cited Papers
- 1 December 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (12)
Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation
Background: The limited effectiveness of endocardial catheter ablation (CA) for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the development of a minimally invasive epicardial/endocardial ablation approach (Hybrid Convergent) to achieve a more comprehensive lesion set with durable transmural lesions. The multicenter randomized controlled CONVERGE trial (Convergence of Epicardial and Endocardial Ablation for the Treatment of Symptomatic Persistent AF) evaluated the safety of Hybrid Convergent and compared its effectiveness to CA for persistent and long-standing persistent AF treatment. Methods: One-hundred fifty-three patients were randomized 2:1 to Hybrid Convergent versus CA. Primary effectiveness was freedom from AF/atrial flutter/atrial tachycardia absent new/increased dosage of previously failed/intolerant class I/III antiarrhythmic drugs through 12 months. Primary safety was major adverse events through 30 days. CONVERGE permitted left atrium size up to 6 cm and imposed no limits on AF duration, making it the only ablation trial to substantially include long-standing persistent–AF, that is, 42% patients with long-standing persistent–AF. Results: Of 149 evaluable patients at 12 months, primary effectiveness was achieved in 67.7% (67/99) patients with Hybrid Convergent and 50.0% (25/50) with CA ( P =0.036) on/off previously failed antiarrhythmic drugs and in 53.5% (53/99) versus 32.0% (16/50; P =0.0128) respectively off antiarrhythmic drugs. At 18 months using 7-day Holter, 74.0% (53/72) Hybrid Convergent and 55% (23/42) CA patients experienced ≥90% AF burden reduction. A total of 2.9% (3/102) patients had primary safety events within 7 days, and 4.9% (5/102) between 8 and 30 days postprocedure. No deaths, cardiac perforations, or atrioesophageal fistulas occurred. All but one primary safety event resolved. Conclusions: The Hybrid Convergent procedure has superior effectiveness compared to the CA for the treatment of persistent and long-standing persistent atrial fibrillation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01984346.
- 1 December 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (12)
Top Cited PapersHybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation
Background: The limited effectiveness of endocardial catheter ablation (CA) for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the development of a minimally invasive epicardial/endocardial ablation approach (Hybrid Convergent) to achieve a more comprehensive lesion set with durable transmural lesions. The multicenter randomized controlled CONVERGE trial (Convergence of Epicardial and Endocardial Ablation for the Treatment of Symptomatic Persistent AF) evaluated the safety of Hybrid Convergent and compared its effectiveness to CA for persistent and long-standing persistent AF treatment. Methods: One-hundred fifty-three patients were randomized 2:1 to Hybrid Convergent versus CA. Primary effectiveness was freedom from AF/atrial flutter/atrial tachycardia absent new/increased dosage of previously failed/intolerant class I/III antiarrhythmic drugs through 12 months. Primary safety was major adverse events through 30 days. CONVERGE permitted left atrium size up to 6 cm and imposed no limits on AF duration, making it the only ablation trial to substantially include long-standing persistent–AF, that is, 42% patients with long-standing persistent–AF. Results: Of 149 evaluable patients at 12 months, primary effectiveness was achieved in 67.7% (67/99) patients with Hybrid Convergent and 50.0% (25/50) with CA ( P =0.036) on/off previously failed antiarrhythmic drugs and in 53.5% (53/99) versus 32.0% (16/50; P =0.0128) respectively off antiarrhythmic drugs. At 18 months using 7-day Holter, 74.0% (53/72) Hybrid Convergent and 55% (23/42) CA patients experienced ≥90% AF burden reduction. A total of 2.9% (3/102) patients had primary safety events within 7 days, and 4.9% (5/102) between 8 and 30 days postprocedure. No deaths, cardiac perforations, or atrioesophageal fistulas occurred. All but one primary safety event resolved. Conclusions: The Hybrid Convergent procedure has superior effectiveness compared to the CA for the treatment of persistent and long-standing persistent atrial fibrillation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01984346.
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , S7
PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , S7
PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)
- Open Access
- 25 March 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (5) , 888-892
A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma
Key Clinical Message: We report a case of lung adenocarcinoma‐associated hypercoagulability leading to venous limb gangrene, managed successfully with argatroban and then dabigatran. Use of idarucizumab permitted diagnostic investigations, leading to targeted antineoplastic therapy with crizotinib, surgical resection with curative intent, and continued survival over 2 years after the index event.
- 25 March 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (5) , 888-892
Open AccessA hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma
Key Clinical Message: We report a case of lung adenocarcinoma‐associated hypercoagulability leading to venous limb gangrene, managed successfully with argatroban and then dabigatran. Use of idarucizumab permitted diagnostic investigations, leading to targeted antineoplastic therapy with crizotinib, surgical resection with curative intent, and continued survival over 2 years after the index event.